IMNM vs. ACAD, MOR, RXRX, XENE, AMRX, CPRX, HCM, BHC, NAMS, and TWST
Should you be buying Immunome stock or one of its competitors? The main competitors of Immunome include ACADIA Pharmaceuticals (ACAD), MorphoSys (MOR), Recursion Pharmaceuticals (RXRX), Xenon Pharmaceuticals (XENE), Amneal Pharmaceuticals (AMRX), Catalyst Pharmaceuticals (CPRX), HUTCHMED (HCM), Bausch Health Companies (BHC), NewAmsterdam Pharma (NAMS), and Twist Bioscience (TWST). These companies are all part of the "pharmaceutical products" industry.
Immunome vs.
ACADIA Pharmaceuticals (NASDAQ:ACAD) and Immunome (NASDAQ:IMNM) are both medical companies, but which is the better stock? We will contrast the two companies based on the strength of their media sentiment, dividends, community ranking, earnings, analyst recommendations, profitability, institutional ownership, valuation and risk.
In the previous week, Immunome had 13 more articles in the media than ACADIA Pharmaceuticals. MarketBeat recorded 27 mentions for Immunome and 14 mentions for ACADIA Pharmaceuticals. Immunome's average media sentiment score of 0.78 beat ACADIA Pharmaceuticals' score of 0.61 indicating that Immunome is being referred to more favorably in the news media.
ACADIA Pharmaceuticals has higher revenue and earnings than Immunome. Immunome is trading at a lower price-to-earnings ratio than ACADIA Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
ACADIA Pharmaceuticals received 860 more outperform votes than Immunome when rated by MarketBeat users. However, 77.08% of users gave Immunome an outperform vote while only 73.05% of users gave ACADIA Pharmaceuticals an outperform vote.
96.7% of ACADIA Pharmaceuticals shares are held by institutional investors. Comparatively, 44.6% of Immunome shares are held by institutional investors. 28.3% of ACADIA Pharmaceuticals shares are held by insiders. Comparatively, 8.6% of Immunome shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.
ACADIA Pharmaceuticals has a beta of 0.43, indicating that its share price is 57% less volatile than the S&P 500. Comparatively, Immunome has a beta of 1.93, indicating that its share price is 93% more volatile than the S&P 500.
ACADIA Pharmaceuticals currently has a consensus target price of $23.93, indicating a potential upside of 39.96%. Immunome has a consensus target price of $25.50, indicating a potential upside of 264.29%. Given Immunome's stronger consensus rating and higher possible upside, analysts plainly believe Immunome is more favorable than ACADIA Pharmaceuticals.
ACADIA Pharmaceuticals has a net margin of 13.83% compared to Immunome's net margin of -3,014.59%. ACADIA Pharmaceuticals' return on equity of 25.83% beat Immunome's return on equity.
Summary
ACADIA Pharmaceuticals beats Immunome on 11 of the 18 factors compared between the two stocks.
Get Immunome News Delivered to You Automatically
Sign up to receive the latest news and ratings for IMNM and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip ChartMedia Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart
Immunome Competitors List
Related Companies and Tools
This page (NASDAQ:IMNM) was last updated on 3/28/2025 by MarketBeat.com Staff